Sino Biopharmaceutical Limited
SBMFF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $8,787 | $8,787 | $6,496 | $6,496 |
| % Growth | 0% | 35.3% | 0% | – |
| Cost of Goods Sold | $1,541 | $1,541 | $1,246 | $1,246 |
| Gross Profit | $7,247 | $7,247 | $5,250 | $5,250 |
| % Margin | 82.5% | 82.5% | 80.8% | 80.8% |
| R&D Expenses | $1,594 | $1,594 | $1,255 | $1,255 |
| G&A Expenses | $547 | $547 | $515 | $515 |
| SG&A Expenses | $3,772 | $3,772 | $2,656 | $2,656 |
| Sales & Mktg Exp. | $3,225 | $3,225 | $2,141 | $2,141 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,365 | $5,365 | $3,911 | $3,911 |
| Operating Income | $1,881 | $1,881 | $1,193 | $1,193 |
| % Margin | 21.4% | 21.4% | 18.4% | 18.4% |
| Other Income/Exp. Net | $1,102 | $1,102 | -$362 | -$362 |
| Pre-Tax Income | $2,983 | $2,983 | $832 | $832 |
| Tax Expense | $491 | $491 | -$182 | -$182 |
| Net Income | $1,694 | $1,694 | $241 | $241 |
| % Margin | 19.3% | 19.3% | 3.7% | 3.7% |
| EPS | 0.094 | 0.094 | 0.014 | 0.014 |
| % Growth | 0% | 572.1% | 0% | – |
| EPS Diluted | 0.094 | 0.094 | 0.014 | 0.014 |
| Weighted Avg Shares Out | 18,024 | 18,024 | 17,244 | 17,244 |
| Weighted Avg Shares Out Dil | 18,026 | 18,026 | 18,180 | 18,180 |
| Supplemental Information | – | – | – | – |
| Interest Income | $928 | $928 | $449 | $449 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $265 | $265 | $235 | $241 |
| EBITDA | $1,969 | $1,969 | $1,084 | $1,090 |
| % Margin | 22.4% | 22.4% | 16.7% | 16.8% |